Septa Pharmaceuticals acquires CeeNU from Bristol Myers Squibb
July 16, 2026 | 15:18
Septa Pharmaceuticals completed its acquisition of CeeNU, or Lomustine, from Bristol Myers Squibb Canada as of 29 June, marking a strategic expansion for the growing Canadian healthcare company.
Mobile Version